Works matching DE "ECULIZUMAB"
Results: 803
Factor B as a therapeutic target for the treatment of complement-mediated diseases.
- Published in:
- Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1537974
- By:
- Publication type:
- Article
Distinction of early complement classical and lectin pathway activation via quantification of C1s/C1-INH and MASP-1/C1-INH complexes using novel ELISAs.
- Published in:
- Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2022.1039765
- By:
- Publication type:
- Article
Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
- Published in:
- Clinical & Experimental Nephrology, 2019, v. 23, n. 1, p. 112, doi. 10.1007/s10157-018-1610-2
- By:
- Publication type:
- Article
Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
- Published in:
- Clinical & Experimental Nephrology, 2019, v. 23, n. 1, p. 65, doi. 10.1007/s10157-018-1609-8
- By:
- Publication type:
- Article
Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
- Published in:
- Clinical & Experimental Nephrology, 2016, v. 20, n. 2, p. 265, doi. 10.1007/s10157-015-1142-y
- By:
- Publication type:
- Article
Effect of dipeptidyl peptidase‐4 inhibitors on complement activation.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2021, v. 37, n. 3, p. 1, doi. 10.1002/dmrr.3385
- By:
- Publication type:
- Article
Comparative Study of the Stability of Eculizumab Biosimilar and the Original Drug under Extreme pH, Oxidative Stress, and UV Irradiation Conditions.
- Published in:
- Pharmaceutical Chemistry Journal, 2021, v. 55, n. 7, p. 732, doi. 10.1007/s11094-021-02485-y
- By:
- Publication type:
- Article
High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Eculizumab in refractory myasthenia gravis: a real-world single-center experience.
- Published in:
- Neurological Sciences, 2025, v. 46, n. 2, p. 951, doi. 10.1007/s10072-024-07861-6
- By:
- Publication type:
- Article
Therapeutic challenges and unmet needs in the management of myasthenia gravis: an Italian expert opinion.
- Published in:
- Neurological Sciences, 2024, v. 45, n. 12, p. 5671, doi. 10.1007/s10072-024-07577-7
- By:
- Publication type:
- Article
Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors.
- Published in:
- Neurological Sciences, 2024, v. 45, n. 3, p. 1243, doi. 10.1007/s10072-023-07190-0
- By:
- Publication type:
- Article
Eculizumab for a catastrophic relapse in NMOSD: case report.
- Published in:
- Neurological Sciences, 2024, v. 45, n. 1, p. 249, doi. 10.1007/s10072-023-06971-x
- By:
- Publication type:
- Article
Eculizumab as a promising rescue therapy for acute exacerbations of myasthenia gravis.
- Published in:
- Neurological Sciences, 2023, v. 44, n. 12, p. 4573, doi. 10.1007/s10072-023-06993-5
- By:
- Publication type:
- Article
Starting eculizumab as rescue therapy in refractory myasthenic crisis.
- Published in:
- Neurological Sciences, 2023, v. 44, n. 10, p. 3707, doi. 10.1007/s10072-023-06900-y
- By:
- Publication type:
- Article
A safe change from eculizumab to satralizumab in a patient with neuromyelitis optica spectrum disorder.
- Published in:
- Neurological Sciences, 2023, v. 44, n. 3, p. 1097, doi. 10.1007/s10072-022-06495-w
- By:
- Publication type:
- Article
Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab.
- Published in:
- Neurological Sciences, 2022, v. 43, n. 7, p. 4081, doi. 10.1007/s10072-022-05922-2
- By:
- Publication type:
- Article
Benefit and danger from immunotherapy in myasthenia gravis.
- Published in:
- Neurological Sciences, 2021, v. 42, n. 4, p. 1367, doi. 10.1007/s10072-021-05077-6
- By:
- Publication type:
- Article
Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis.
- Published in:
- 2019
- By:
- Publication type:
- corrected article
Eculizumab improves fatigue in refractory generalized myasthenia gravis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
JAK/STAT inhibition augments soleus muscle function in a rat model of critical illness myopathy via regulation of complement C3/3R.
- Published in:
- Journal of Physiology, 2021, v. 599, n. 11, p. 2869, doi. 10.1113/JP281220
- By:
- Publication type:
- Article
Xenotransplantation literature update, March-April 2016.
- Published in:
- Xenotransplantation, 2016, v. 23, n. 3, p. 249, doi. 10.1111/xen.12241
- By:
- Publication type:
- Article
Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series.
- Published in:
- Brain Sciences (2076-3425), 2021, v. 11, n. 10, p. 1341, doi. 10.3390/brainsci11101341
- By:
- Publication type:
- Article
Management of haemophilia A with inhibitors: A regional cross‐talk.
- Published in:
- Haemophilia, 2022, v. 28, n. 6, p. 950, doi. 10.1111/hae.14638
- By:
- Publication type:
- Article
Plasma levels of mannan-binding lectin-associated serine proteases are increased in type 1 diabetes patients with insulin resistance.
- Published in:
- Clinical & Experimental Immunology, 2024, v. 215, n. 1, p. 58, doi. 10.1093/cei/uxad113
- By:
- Publication type:
- Article
Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 214, n. 2, p. 209, doi. 10.1093/cei/uxad088
- By:
- Publication type:
- Article
Differentiating between activation via the lectin or the classical complement pathway in patients with systemic lupus erythematosus.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 214, n. 1, p. 18, doi. 10.1093/cei/uxad070
- By:
- Publication type:
- Article
MASP2 inhibition by narsoplimab suppresses endotheliopathies characteristic of transplant-associated thrombotic microangiopathy: in vitro and ex vivo evidence.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 213, n. 2, p. 252, doi. 10.1093/cei/uxad055
- By:
- Publication type:
- Article
miR-132-3p regulates antibody-mediated complement-dependent cytotoxicity in colon cancer cells by directly targeting CD55.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 211, n. 1, p. 57, doi. 10.1093/cei/uxac120
- By:
- Publication type:
- Article
Elevated expression of TAM receptor tyrosine kinase in synovial fluid and synovial tissue of rheumatoid arthritis.
- Published in:
- Clinical & Experimental Immunology, 2022, v. 209, n. 3, p. 270, doi. 10.1093/cei/uxac071
- By:
- Publication type:
- Article
MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti‐MASP2 antibody narsoplimab.
- Published in:
- Clinical & Experimental Immunology, 2021, v. 203, n. 1, p. 96, doi. 10.1111/cei.13497
- By:
- Publication type:
- Article
Carbamylation reduces the capacity of IgG for hexamerization and complement activation.
- Published in:
- Clinical & Experimental Immunology, 2020, v. 200, n. 1, p. 1, doi. 10.1111/cei.13411
- By:
- Publication type:
- Article
Multi‐component meningococcal serogroup B (MenB)‐4C vaccine induces effective opsonophagocytic killing in children with a complement deficiency.
- Published in:
- Clinical & Experimental Immunology, 2019, v. 198, n. 3, p. 381, doi. 10.1111/cei.13368
- By:
- Publication type:
- Article
Complement component 5 does not interfere with physiological hemostasis but is essential for Escherichia coli‐induced coagulation accompanied by Toll‐like receptor 4.
- Published in:
- Clinical & Experimental Immunology, 2019, v. 196, n. 1, p. 97, doi. 10.1111/cei.13240
- By:
- Publication type:
- Article
Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
- Published in:
- Clinical & Experimental Immunology, 2017, v. 187, n. 2, p. 304, doi. 10.1111/cei.12890
- By:
- Publication type:
- Article
The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load.
- Published in:
- Clinical & Experimental Immunology, 2015, v. 181, n. 3, p. 457, doi. 10.1111/cei.12645
- By:
- Publication type:
- Article
Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
- Published in:
- Nephrology, 2018, v. 23, n. 6, p. 539, doi. 10.1111/nep.13054
- By:
- Publication type:
- Article
Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab.
- Published in:
- Nephrology, 2017, v. 22, p. 4, doi. 10.1111/nep.12931
- By:
- Publication type:
- Article
Long-term remission with eculizumab in atypical haemolytic uraemic syndrome.
- Published in:
- Nephrology, 2017, v. 22, p. 7, doi. 10.1111/nep.12932
- By:
- Publication type:
- Article
Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab.
- Published in:
- Nephrology, 2017, v. 22, p. 18, doi. 10.1111/nep.12935
- By:
- Publication type:
- Article
De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab.
- Published in:
- Nephrology, 2017, v. 22, p. 23, doi. 10.1111/nep.12936
- By:
- Publication type:
- Article
Absence of thrombocytopaenia and/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation.
- Published in:
- Nephrology, 2017, v. 22, p. 28, doi. 10.1111/nep.12937
- By:
- Publication type:
- Article
Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab.
- Published in:
- Nephrology, 2017, v. 22, p. 32, doi. 10.1111/nep.12938
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Nephrology, 2017, v. 22, p. 1, doi. 10.1111/nep.12962
- Publication type:
- Article
Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
- Published in:
- Nephrology, 2016, v. 21, p. 35, doi. 10.1111/nep.12768
- By:
- Publication type:
- Article
Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
- Published in:
- Nephrology, 2016, v. 21, p. 9, doi. 10.1111/nep.12776
- By:
- Publication type:
- Article
Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab.
- Published in:
- Nephrology, 2016, v. 21, n. 3, p. 261, doi. 10.1111/nep.12582
- By:
- Publication type:
- Article
Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia.
- Published in:
- Bone Marrow Transplantation, 2014, v. 49, n. 8, p. 1116, doi. 10.1038/bmt.2014.97
- By:
- Publication type:
- Article
Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.
- Published in:
- Kidney & Blood Pressure Research, 2020, v. 45, n. 6, p. 939, doi. 10.1159/000510612
- By:
- Publication type:
- Article
Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Relapse of Atypical Hemolytic Uremic Syndrome During Pregnancy in a Patient on Eculizumab Maintenance Treatment: A Case Report.
- Published in:
- American Journal of Case Reports, 2019, v. 20, p. 1460, doi. 10.12659/AJCR.916994
- By:
- Publication type:
- Article